Research has demonstrated that a significant proportion of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphomas overexpress CD7, rendering it a promising target for the treatment of these malignancies (14, 15). Here, CD7 is linked to acute lymphoblastic leukemia.